PLANO, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract development and manufacturing organization (CDMO), will participate in the Piper Sandler 36th Annual Healthcare Conference, to be held Dec. 3 – 5 in New York City. Integer President and Chief Executive Officer Joseph Dziedzic is scheduled to present Tuesday, Dec. 3, 2024, at 10:30 a.m. EST.
The presentation will be accessible via a live webcast. The link to the live webcast may also be accessed under “News & Events” on the Investor Relations section of the Integer website at investor.integer.net.
Learn more about Integer at www.integer.net.
About Integer®
Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, Integer is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The company's brands include Greatbatch Medical® and Lake Region Medical®. Additional information is available at www.integer.net.
| Investor Relations: Andrew Senn This email address is being protected from spambots. You need JavaScript enabled to view it. 763.951.8312 | Media Relations: Kelly Butler This email address is being protected from spambots. You need JavaScript enabled to view it. 214.618.4216 |
| Last Trade: | US$133.37 |
| Daily Change: | -0.15 -0.11 |
| Daily Volume: | 112,598 |
| Market Cap: | US$4.470B |
October 24, 2024 September 23, 2024 August 22, 2024 July 25, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
